Many biopharma companies raised funds in 2022, but not enough to reach their next milestone. Investors have been constricting investments, so companies needing additional funding require a larger toolbox.
https://www.pharmalive.com/wp-content/uploads/2022/11/NoelDonnelly-PepGen.jpeg350625BioSpacehttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngBioSpace2022-11-28 08:56:192022-11-28 08:56:19Recession survival strategies for newly public biopharma companies